Trial · NCT01783860
Oral Azithromycin Versus Doxycycline in Posterior Blepharitis
NCT01783860, Phase 2, Completed, Tehran University of Medical Sciences; results first posted 2014-02-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Oral Azithromycin Versus Doxycycline in Posterior Blepharitis. Trials, record NCT01783860. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01783860
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Oral Azithromycin Versus Doxycycline in Posterior Blepharitis
- NCT number
- NCT01783860
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 100 participants, actual
- Lead sponsor
- Tehran University of Medical Sciences
- Conditions
- Posterior Blepharitis
- Interventions
- Azithromycin, Doxycycline
- First posted
- 2013-02-05
- Last updated
- 2014-02-12
- Results first posted
- 2014-02-12
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change of Blepharitis Symptoms Score | Change from the baseline until 61 days after treatment | Five main ocular symptoms of posterior blepharitis (itching, foreign body sensation, dryness, burning, and lid swelling) will be asked of each patient and graded at baseline, and days 7, 31, 37 and 61 after treatment. For each item there was a question with scale from zero to three (zero for no symptom three for maximum symptom). Therefore, maximum score for symptoms was 15 (worse outcome) and minimum score for symptoms was zero (better outcome). Finally, we reported a change in total score calculated as the latest time point (61 days) minus the earliest time point. |
| Primary | Change of Symptoms and Signs Scores (Difference Between Total Score of First Time and 61 Days Later), Total Severity Score | zero time and 61 days later | Total severity score was a combined score of symptoms and signs. For symptoms, there were five items and for signs there were seven items. Each items had three scales form Zero (no symptom) to three (severe symptom). Therefore, there was 12 items to calculate total severity score. Maximum score was 36 (worse outcome) and minimum score was zero (better outcome). A change in total severity score calculated as the latest time period (61 days) minus earliest time point. |
| Secondary | Main Ocular Signs | Change from baseline until 61 days after treatment | lid margin debris, lid margin redness, Meibomian gland (MG) secretion, occluded MG, conjunctival redness, tear brake up time and ocular surface staining at Baseline, and days 7, 31, 37 and 61 after treatment were measured. For each items there was a question with scale form zero to three (zero for no sign to three for maximum sign). Therefore, maximum score for signs was 21 (worse outcome) and minimum score was zero (better outcome). We calculated a total score for signs. Finally, we reported a change in total score calculated as the latest time point (61 days) minus earliest time point. |
| Other | Change of Total Severity Score Between Baseline and 7 Days Later | baseline and 7 days later | Total severity score was a combined score of symptoms and signs. For symptoms, there were five items and for signs there were seven items. Each items had three scales form Zero (no symptom) to three (severe symptom). Therefore, there was 12 items to calculate total severity score. Maximum score was 36 (worse outcome) and minimum score was zero (better outcome). A change in total severity score calculated as the latest time period (7 days) minus earliest time point. |
| Other | Change of Total Severity Score Between Baseline and 31 Days Later | baseline and 31 days later | Total severity score was a combined score of symptoms and signs. For symptoms, there were five items and for signs there were seven items. Each items had three scales form Zero (no symptom) to three (severe symptom). Therefore, there was 12 items to calculate total severity score. Maximum score was 36 (worse outcome) and minimum score was zero (better outcome). A change in total severity score calculated as the latest time period (31 days) minus earliest time point. |
| Other | Change of Total Severity Score Between Baseline and 37 Days Later | baseline and 37 days later | Total severity score was a combined score of symptoms and signs. For symptoms, there were five items and for signs there were seven items. Each items had three scales form Zero (no symptom) to three (severe symptom). Therefore, there was 12 items to calculate total severity score. Maximum score was 36 (worse outcome) and minimum score was zero (better outcome). A change in total severity score calculated as the latest time period (37 days) minus earliest time point. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change of Blepharitis Symptoms Score | Change from the baseline until 61 days after treatment | score | MEAN | |
| SECONDARY | Main Ocular Signs | Change from baseline until 61 days after treatment | units on a scale | MEAN | |
| PRIMARY | Change of Symptoms and Signs Scores (Difference Between Total Score of First Time and 61 Days Later), Total Severity Score | zero time and 61 days later | units on a scale | MEAN | |
| OTHER_PRE_SPECIFIED | Change of Total Severity Score Between Baseline and 7 Days Later | baseline and 7 days later | units on a scale | MEAN | |
| OTHER_PRE_SPECIFIED | Change of Total Severity Score Between Baseline and 31 Days Later | baseline and 31 days later | units on a scale | MEAN | |
| OTHER_PRE_SPECIFIED | Change of Total Severity Score Between Baseline and 37 Days Later | baseline and 37 days later | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change of Blepharitis Symptoms Score | Doxycycline | 1.8 | Standard Deviation 2.5 | score | |
| Change of Blepharitis Symptoms Score | Oral Azithromycin | 2.8 | Standard Deviation 2.2 | score | |
| Main Ocular Signs | Doxycycline | 4.7 | Standard Deviation 2.3 | units on a scale | |
| Main Ocular Signs | Oral Azithromycin | 5.7 | Standard Deviation 2.0 | units on a scale | |
| Change of Symptoms and Signs Scores (Difference Between Total Score of First Time and 61 Days Later), Total Severity Score | Doxycycline | 6.5 | Standard Deviation 4.1 | units on a scale | |
| Change of Symptoms and Signs Scores (Difference Between Total Score of First Time and 61 Days Later), Total Severity Score | Oral Azithromycin | 8.6 | Standard Deviation 3.6 | units on a scale | |
| Change of Total Severity Score Between Baseline and 7 Days Later | Doxycycline | 3.9 | Standard Deviation 2.5 | units on a scale | |
| Change of Total Severity Score Between Baseline and 7 Days Later | Oral Azithromycin | 4.3 | Standard Deviation 2.6 | units on a scale | |
| Change of Total Severity Score Between Baseline and 31 Days Later | Doxycycline | 5.2 | Standard Deviation 2.4 | units on a scale | |
| Change of Total Severity Score Between Baseline and 31 Days Later | Oral Azithromycin | 6.4 | Standard Deviation 2.6 | units on a scale |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Doxycycline | 50 | |
| Overall Study | STARTED | Oral Azithromycin | 50 | |
| Overall Study | COMPLETED | Doxycycline | 50 | |
| Overall Study | COMPLETED | Oral Azithromycin | 50 | |
| Overall Study | NOT COMPLETED | Doxycycline | 0 | |
| Overall Study | NOT COMPLETED | Oral Azithromycin | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | vomiting and loss of appetide | Gastrointestinal disorders | Doxycycline | 12 | 50 | |
| serious | vomiting and loss of appetide | Gastrointestinal disorders | Oral Azithromycin | 3 | 50 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Doxycycline | ||
| Total, all-cause mortality | Oral Azithromycin | ||
| Total, other adverse events | Doxycycline | 0 | 50 |
| Total, other adverse events | Oral Azithromycin | 0 | 50 |
| Total, serious adverse events | Doxycycline | 12 | 50 |
| Total, serious adverse events | Oral Azithromycin | 3 | 50 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 25138765 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Doxycycline vs Oral Azithromycin: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01783860
GET https://conductscience.org/api/trials/v1/NCT01783860/registered